Out With Experimentation, ZS Sees New Commercial Models Settling In
This article was originally published in The Pink Sheet Daily
After several years of experimentation, big pharma has settled on new commercial models for their U.S. sales teams and are in various stages of implementation, according to ZS Associates Managing Director Chris Wright. The preferred models have commonalities built around a mix of traditional sales reps, key account managers and multi-channel digital tools.
You may also be interested in...
Sanofi’s North America Pharma Head Whitaker Implements Patient Solution Responses to Commercial Challenges
Since joining Sanofi as president of its North American Pharmaceuticals and Consumer Healthcare Businesses in mid-2011, Anne Whitaker has made important changes in the commercial organization to address the evolving market at a critical time for the company.
About a year into GSK’s innovative sales force incentive program, Jack Bailey, head of payers, policy and vaccines, provides an update on the company’s strategy in an interview with “The Pink Sheet” DAILY.
In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?